DAVID A. CHERRILL, M.D.; ROBERT M. STOTE, M.D.; JAMES R. BIRGE, M.D.; IRWIN SINGER, M.D., F.A.C.P.
We have studied the effects of demeclocycline on the water metabolism of a patient with the syndrome of inappropriate antidiuretic hormone (ADH) secretion who presented with a serum sodium concentration of 110 meq/litre. Free water clearance was studied before, during, and after treatment with demeclocycline. This study shows that demeclocycline (900 mg/day) can at least partially inhibit the action of ADH in the setting of tumor-induced ADH secretion, with the production of a reversible, partial nephrogenic diabetes insipidus, and with few or no side effects. Demeclocycline may be useful in the treatment of chronic inappropriate ADH secretion.
CHERRILL DA, STOTE RM, BIRGE JR, SINGER I. Demeclocycline Treatment in the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Ann Intern Med. ;83:654–656. doi: 10.7326/0003-4819-83-5-654
Download citation file:
Published: Ann Intern Med. 1975;83(5):654-656.
Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use